Monoclonal antibodies (mAbs) are nature's biological warheads, able to target and help eliminate foreign or abnormal agents from the body. In theory, replicating this powerful defense system could ...

Monoclonal antibodies (mAbs) can achieve unparalleled affinity and specificity for a wide range of biomolecules, making the reagents critical to both basic and clinical research. The vast majority ...

A Golden Gate-based dual-expression vector enables rapid screening, which facilitates efficient isolation of high-affinity cross-reactive antibodies for therapeutic or diagnostic use and provides a ...

With the invention of hybridoma technology in 1975, monoclonal antibodies (mABs) have undergone significant advancements and ...

Monoclonal antibodies (mAbs) have revolutionized cancer therapy due to their ability to specifically target tumor cells while ...

Researchers suggest broadly reactive antibodies identified are likely to represent a common mechanism of acquired immunity to ...

Stock recommendation on SIGA Technologies affected by mpox outbreak response, diversifying into mAbs for orthopoxviruses, remains speculative buy.

Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable TherapeuticsJUPITER, Fla., Nov. 21, ...

Adagene Inc. (NASDAQ:ADAG – Get Free Report) was the target of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 1,500 shares, a ...

Casirivimab and imdevimab in combination is safe among pediatric outpatients with at least 1 risk factor for severe COVID-19.

Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System AtrophyMASCOT, a global phase III randomized, double-blind, placebo-controlled trial, will assess the efficacy ...

Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...